BY PETER HYSLOP
The Hunter Medical Research Institute says it will have greater capacity to provide new clinical treatments for cardiovascular disease.
The institute has signed a memorandum of understanding with pharmaceutical giant Novartis, to explore new research opportunities.
Chief executive FRANCES KAY-LAMBKIN says she hopes more treatments are on the way.
Novartis Australia and New Zealand President Matt Zeller says the partnership is an important step for advancing quality treatment.
“Cardiovascular disease is still the leading cause of death in Australia, and we must be willing to work together, across the ecosystem, to try new things and see what can actually reduce the burden on communities, patients, and their families," he said.
HMRI Chief Executive Professor Frances Kay-Lambkin says it will fast-track research into practice.
"Traditionally, it can take up to 17 years for research discoveries to make it from the lab to the hands of clinicians. Collaborations like this with Novartis provide the additional funding, resources, and linkages needed to significantly shorten that timeline, directly benefiting patients and the broader community," she said.
 |
| Researcher in action. Credit: HMRI |
